Singapore markets closed

AVIR Oct 2024 5.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.2000-0.1500 (-42.86%)
As of 09:36AM EDT. Market open.
Full screen
Previous close0.3500
Open0.2000
Bid0.1500
Ask0.3000
Strike5.00
Expiry date2024-10-18
Day's range0.2000 - 0.2000
Contract rangeN/A
Volume21
Open interest269
  • GuruFocus.com

    Atea Pharmaceuticals Inc (AVIR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...

    Discover key updates on Atea's financial health, clinical advancements, and strategic outlook as they pave the way through 2024.

  • GlobeNewswire

    Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

    Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-s

  • GlobeNewswire

    Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024

    BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call